Show simple item record

dc.contributor.authorHernández, Adrian V.*
dc.contributor.authorGuarnizo, Mirella*
dc.contributor.authorMiranda, Yony*
dc.contributor.authorPasupuleti, Vinay*
dc.contributor.authorDeshpande, Abhishek*
dc.contributor.authorPaico, Socorro*
dc.contributor.authorLenti, Hosten*
dc.contributor.authorGanoza, Silvia*
dc.contributor.authorMontalvo, Laritza*
dc.contributor.authorThota, Priyaleela*
dc.contributor.authorLazaro, Herbert*
dc.date.accessioned2014-06-10T00:40:22Z
dc.date.available2014-06-10T00:40:22Z
dc.date.issued2014-06-09
dc.identifier.citationPLoS ONE 9(6): e99317es_PE
dc.identifier.doi10.1371/journal.pone.0099317
dc.identifier.urihttp://hdl.handle.net/10757/320267es_PE
dc.descriptionThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.eng
dc.description.abstractObjective: This study was undertaken to evaluate the association between components defining insulin resistance and breast cancer in women. Study Design: We conducted a systematic review of four databases (PubMed-Medline, EMBASE, Web of Science, and Scopus) for observational studies evaluating components defining insulin resistance in women with and without breast cancer. A meta-analysis of the association between insulin resistance components and breast cancer was performed using random effects models. Results: Twenty-two studies (n = 33,405) were selected. Fasting insulin levels were not different between women with and without breast cancer (standardized mean difference, SMD 20.03, 95%CI 20.32 to 0.27; p = 0.9). Similarly, non-fasting/ fasting C-peptide levels were not different between the two groups (mean difference, MD 0.07, 20.21 to 0.34; p = 0.6). Using individual odds ratios (ORs) adjusted at least for age, there was no higher risk of breast cancer when upper quartiles were compared with the lowest quartile (Q1) of fasting insulin levels (OR Q2 vs. Q1 0.96, 0.71 to 1.28; OR Q3 vs. Q1 1.22, 0.91 to 1.64; OR Q4 vs. Q1 0.98, 0.70 to 1.38). Likewise, there were no differences for quartiles of non-fasting/fasting C-peptide levels (OR Q2 vs. Q1 1.12, 0.91 to 1.37; OR Q3 vs. Q1 1.20, 0.91 to 1.59; OR Q4 vs. Q1 1.40, 1.03 to 1.92). Homeostatic model assessment (HOMAIR) levels in breast cancer patients were significantly higher than in people without breast cancer (MD 0.22, 0.13 to 0.31, p, 0.00001). Conclusions: Higher levels of fasting insulin or non-fasting/fasting C-peptide are not associated with breast cancer in women. HOMA-IR levels are slightly higher in women with breast cancer.
dc.description.sponsorshipThis study was funded by the Instituto Me´dico de la Mujer, Lima, Peru. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.eng
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherPublic Library of Science (PLoS)es_PE
dc.relation.urlhttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0099317es_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.subjectBreast cancereng
dc.subjectInsulineng
dc.subjectInsulin resistenceeng
dc.titleAssociation between Insulin Resistance and Breast Carcinoma: A Systematic Review and Meta-Analysises_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.eissn1932-6203
dc.identifier.journalPLoS ONEes_PE
dc.description.peer-reviewRevisión por pareses_PE
refterms.dateFOA2018-06-16T09:14:32Z
html.description.abstractObjective: This study was undertaken to evaluate the association between components defining insulin resistance and breast cancer in women. Study Design: We conducted a systematic review of four databases (PubMed-Medline, EMBASE, Web of Science, and Scopus) for observational studies evaluating components defining insulin resistance in women with and without breast cancer. A meta-analysis of the association between insulin resistance components and breast cancer was performed using random effects models. Results: Twenty-two studies (n = 33,405) were selected. Fasting insulin levels were not different between women with and without breast cancer (standardized mean difference, SMD 20.03, 95%CI 20.32 to 0.27; p = 0.9). Similarly, non-fasting/ fasting C-peptide levels were not different between the two groups (mean difference, MD 0.07, 20.21 to 0.34; p = 0.6). Using individual odds ratios (ORs) adjusted at least for age, there was no higher risk of breast cancer when upper quartiles were compared with the lowest quartile (Q1) of fasting insulin levels (OR Q2 vs. Q1 0.96, 0.71 to 1.28; OR Q3 vs. Q1 1.22, 0.91 to 1.64; OR Q4 vs. Q1 0.98, 0.70 to 1.38). Likewise, there were no differences for quartiles of non-fasting/fasting C-peptide levels (OR Q2 vs. Q1 1.12, 0.91 to 1.37; OR Q3 vs. Q1 1.20, 0.91 to 1.59; OR Q4 vs. Q1 1.40, 1.03 to 1.92). Homeostatic model assessment (HOMAIR) levels in breast cancer patients were significantly higher than in people without breast cancer (MD 0.22, 0.13 to 0.31, p, 0.00001). Conclusions: Higher levels of fasting insulin or non-fasting/fasting C-peptide are not associated with breast cancer in women. HOMA-IR levels are slightly higher in women with breast cancer.


Files in this item

Thumbnail
Name:
AVHernandez PLoSOne2014.pdf
Size:
1.386Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record